Rita King, CEO of MethodSense, provides her expertise on the integration of AI in medical devices and key developments for pharmacists as the technology evolves.
|Slideshows|June 11, 2019
- Drug Topics June 2019
- Volume 163
- Issue 6
Maintain Control of Controlled Substances
Author(s)Natalia Mazina, JD
Comply with state and federal regulations on dispensing and handling controls to avoid possible disciplinary or DEA actions and penalties.
Advertisement
Articles in this issue
over 7 years ago
Opinion: Data is a Vital Resource in Fighting the Opioid Crisisover 7 years ago
Why Technology Upkeep is Up to Youover 7 years ago
Five Tech Best Practicesover 7 years ago
New Drug Review: Zulresso (Brexanolone)over 7 years ago
Opinion: The Future of Pharmacyover 7 years ago
Discount Drug Cards Are Flourishingover 7 years ago
How to Keep Your Professional Development Currentover 7 years ago
10 Ways to Boost Customer Loyaltyover 7 years ago
Opinion: PharmD Quality vs Quantityover 7 years ago
On the Road to Provider StatusAdvertisement
Related to this article
Harini Bupathi, Esq, explains why pharmacies need to continue prioritizing PBM relationships despite rapid legislative change.
Researchers assessed the extent of which vaccine fatigue translates to reduced engagement and adherence among patients.
Brianne Porter, PharmD, MS, explores how pharmacists can deliver care to a population of women experiencing life-altering symptoms of urinary incontinence.
AJ Barbarito, Esq, explains how ERISA and Medicare Part D preemption limit state PBM laws and why a private right of action may be the most effective path forward.
Approval was given to GSK, making its product the first antisense oligonucleotide established for the treatment of chronic hepatitis B.
With safety and efficacy profiles aligning with its brand-name formulation, this new patch could be key for women struggling with hormone therapy adherence.
Investigators link oversight with eroding trust in health authorities and call on future pandemic inquiries to weigh trade-offs.
Advertisement
Advertisement
Trending on Drug Topics
1
PBM Underpayment Persists as Cost-Plus Brings New Strain | NCPA 2026
2
Q&A: Why Enforcement Is the Weak Link in State PBM Reform | NCPA 2026
3
PBM Network Terminations Bring Risks Beyond Lost Contracts | NCPA 2026
4
FDA Approves Bepirovirsen Injection to Treat Chronic Hepatitis B
5